ICAM-1 Antisense Oligonucleotide With Lower Toxicity and Cost

The patent changes the chemical parameters of the oligonucleotide by using 2'-O-methyl modifications instead of more advanced LNA modifications, and uses a standard phosphate backbone instead of phosphorothioate. This parameter change maintains sufficient biological potency while dramatically reducing production costs, as 2'-O-methyl modifications are less expensive to manufacture than LNA while still providing the necessary stability and binding affinity for ICAM-1 suppression.

The patent employs a cost-effective oligonucleotide design that uses readily available, inexpensive chemical building blocks (2'-O-methyl nucleotides with standard phosphate backbone) rather than expensive modified nucleotides. This approach treats the oligonucleotide as a disposable therapeutic agent that can be produced economically for repeated administrations, aligning with the principle of using cheap, short-living objects when longevity is not the primary constraint.

The patent optimizes the chemical parameters of the oligonucleotide by selecting 2'-O-methyl modifications and a standard phosphate backbone, which change the physical and chemical properties to achieve the right balance. This parameter optimization provides sufficient stability and binding affinity for effective ICAM-1 suppression while reducing the immunostimulatory effects associated with phosphorothioate modifications and avoiding the toxicity concerns of more potent but less selective agents.

The patent applies chemical modifications (2'-O-methyl) specifically at the sugar moiety of the nucleotide while leaving the phosphate backbone unmodified. This local quality approach provides enhanced stability and binding affinity where needed (in the sugar region) while avoiding the immunostimulatory effects associated with backbone modifications like phosphorothioates, thus achieving local optimization of efficacy versus safety.